388 related articles for article (PubMed ID: 34241938)
1. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
Napolitano M; Di Guida A; Fabbrocini G; Patruno C
Dermatol Ther; 2021 Sep; 34(5):e15059. PubMed ID: 34241938
[TBL] [Abstract][Full Text] [Related]
2. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
3. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
[TBL] [Abstract][Full Text] [Related]
4. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
5. Ocular Adverse Events in Patients With Atopic Dermatitis Treated With Upadacitinib: A Real-Life Experience.
Gelato F; Mastorino L; Quaglino P; Cavaliere G; Ortoncelli M; Ribero S
Dermatitis; 2023; 34(5):445-447. PubMed ID: 36917522
[No Abstract] [Full Text] [Related]
6. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
[TBL] [Abstract][Full Text] [Related]
7. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
[TBL] [Abstract][Full Text] [Related]
8. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
Agnihotri G; Shi K; Lio PA
Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
[TBL] [Abstract][Full Text] [Related]
9. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
Stein Gold L; Thaçi D; Thyssen JP; Gooderham M; Laquer V; Moore A; Natalie CR; Zhao F; Meskimen E; Elmaraghy H; Montmayeur S; Gallo G; Jimenez G; de Bruin-Weller M
Am J Clin Dermatol; 2023 Jul; 24(4):595-607. PubMed ID: 37195407
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab for atopic dermatitis: evidence to date.
Rodrigues MA; Nogueira M; Torres T
G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
[TBL] [Abstract][Full Text] [Related]
11. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
13. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center.
Parmar NV; Abdula MA; Al Falasi A; Krishna CV
Dermatol Ther; 2022 May; 35(5):e15415. PubMed ID: 35238115
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Treister AD; Kraff-Cooper C; Lio PA
JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
[TBL] [Abstract][Full Text] [Related]
16. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.
Ou Z; Chen C; Chen A; Yang Y; Zhou W
Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study.
Barbé J; Poreaux C; Remen T; Schoeffler A; Cloché V; Schmutz JL; Escobar G; Busztejn AC
Int J Dermatol; 2021 Dec; 60(12):1520-1528. PubMed ID: 34037253
[TBL] [Abstract][Full Text] [Related]
19. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
[TBL] [Abstract][Full Text] [Related]
20. Real-life effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
Salman A; Apti Sengun Ö; Aktas M; Taşkapan O
Dermatol Ther; 2022 Jan; 35(1):e15192. PubMed ID: 34743366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
